Advertisement

Latent variable indirect response modeling of categorical endpoints representing change from baseline

  • Chuanpu Hu
  • Zhenhua Xu
  • Alan M. Mendelsohn
  • Honghui Zhou
Original Paper

Abstract

Accurate exposure–response modeling is important in drug development. Methods are still evolving in the use of mechanistic, e.g., indirect response (IDR) models to relate discrete endpoints, mostly of the ordered categorical form, to placebo/co-medication effect and drug exposure. When the discrete endpoint is derived using change-from-baseline measurements, a mechanistic exposure–response modeling approach requires adjustment to maintain appropriate interpretation. This manuscript describes a new modeling method that integrates a latent-variable representation of IDR models with standard logistic regression. The new method also extends to general link functions that cover probit regression or continuous clinical endpoint modeling. Compared to an earlier latent variable approach that constrained the baseline probability of response to be 0, placebo effect parameters in the new model formulation are more readily interpretable and can be separately estimated from placebo data, thus allowing convenient and robust model estimation. A general inherent connection of some latent variable representations with baseline-normalized standard IDR models is derived. For describing clinical response endpoints, Type I and Type III IDR models are shown to be equivalent, therefore there are only three identifiable IDR models. This approach was applied to data from two phase III clinical trials of intravenously administered golimumab for the treatment of rheumatoid arthritis, where 20, 50, and 70 % improvement in the American College of Rheumatology disease severity criteria were used as efficacy endpoints. Likelihood profiling and visual predictive checks showed reasonable parameter estimation precision and model performance.

Keywords

Discrete variable Population pharmacokinetic/pharmacodynamic modeling NONMEM Golimumab Rheumatoid arthritis 

Notes

Acknowledgments

The authors thank the anonymous reviewers for their insightful and constructive suggestions and the Medical Affairs Publications Group of Janssen Services, LLC, for their editorial support.

References

  1. 1.
    Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457–478PubMedCrossRefGoogle Scholar
  2. 2.
    Woo S, Pawaskar D, Jusko WJ (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36(5):381–405PubMedCrossRefGoogle Scholar
  3. 3.
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735PubMedCrossRefGoogle Scholar
  4. 4.
    Mandema JW, Stanski DR (1996) Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 60(6):619–635PubMedCrossRefGoogle Scholar
  5. 5.
    Hutmacher MM, Krishnaswami S, Kowalski KG (2008) Exposure–response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 35(2):139–157PubMedCrossRefGoogle Scholar
  6. 6.
    Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE (2009) A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther 86(4):387–395PubMedCrossRefGoogle Scholar
  7. 7.
    Hu C, Xu Z, Rahman MU, Davis HM, Zhou H (2010) A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. J Pharmacokinet Pharmacodyn 37(4):309–321PubMedCrossRefGoogle Scholar
  8. 8.
    Hutmacher MM, French JL (2011) Extending the latent variable model for extra correlated longitudinal dichotomous responses. J Pharmacokinet Pharmacodyn 38(6):833–859PubMedCrossRefGoogle Scholar
  9. 9.
    Hu C, Szapary PO, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237–260PubMedCrossRefGoogle Scholar
  10. 10.
    Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497–517PubMedCrossRefGoogle Scholar
  11. 11.
    Simponi [package insert] (2011) Janssen Biotech, Inc. Horsham, PAGoogle Scholar
  12. 12.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P (2010) Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight–week efficacy and safety results of a phase III, randomized, double-blind, placebo-controlled study. Arthritis Rheum 62(4):917–928PubMedCrossRefGoogle Scholar
  13. 13.
    Weinblatt ME, Bingham CO III, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R (2012) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-201411
  14. 14.
    Hu C, Zhou H (2008) An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol 48(7):812–822PubMedCrossRefGoogle Scholar
  15. 15.
    Cox DR, Hinkley DV (1979) Theoretical statistics. Chapman & Hall/CRC Press LLC, Boca RatonGoogle Scholar
  16. 16.
    Karlsson MO, Holford N (2008) A tutorial on visual predictive checks. Population Approach Group in Europe. Abstract 1434. http://www.page-meeting.org/?abstract=1434. Accessed 20 Dec 2012
  17. 17.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009) Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272–2283PubMedCrossRefGoogle Scholar
  18. 18.
    Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU (2009) Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789–796PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Chuanpu Hu
    • 1
  • Zhenhua Xu
    • 1
  • Alan M. Mendelsohn
    • 2
  • Honghui Zhou
    • 1
  1. 1.Pharmacokinetics and Pharmacometrics, Biologics Clinical PharmacologyJanssen Research & Development, LLCSpring HouseUSA
  2. 2.Clinical ImmunologyJanssen Research & Development, LLCSpring HouseUSA

Personalised recommendations